14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BGM vs IRWD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas IRWD carries 37.8/100 (SELL) at $4.70 (12.3x Forward P/E, 62.9% operating margin).
Composite vs. Pillar Nuance: While BGM currently prints a higher short-term Unified Composite Score (59.6/100 HOLD vs. IRWD 37.8/100 SELL), IRWD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -23.4% operating margin) and revenue trajectory (+9.0% vs. +69.8% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs IRWD. Trailing 12-month operating profitability (BGM -23.4% vs IRWD 62.9%) and valuation multiples (BGM N/M vs IRWD 12.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment40.3% of Rev ($19M)
90D Engineering Disclosures0 Published
IRWD Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $779.7M market capitalization and 62.9% operating margin.
OpEx & R&D Reinvestment13.5% of Rev ($54M)
90D Engineering Disclosures0 Published
Investor FAQ BGM vs IRWD Key Questions & Quantitative Answers
As of Nov 20, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas IRWD carries 37.8/100 (SELL) at $4.70 (12.3x Forward P/E, 62.9% operating margin). Composite vs. Pillar Nuance: While BGM currently prints a higher short-term Unified Composite Score (59.6/100 HOLD vs. IRWD 37.8/100 SELL), IRWD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -23.4% operating margin) and revenue trajectory (+9.0% vs. +69.8% YoY).
IRWD leads the Growth & Scale pillar: BGM posts +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin), compared with IRWD at +9.0% YoY revenue growth and +57.0% YoY earnings growth on $400M TTM revenue (76.4% gross margin, 62.9% operating margin). On trailing 12-month operating scale, BGM generates $48M in USD-normalized revenue versus $400M for IRWD. In operating R&D and SG&A reinvestment, BGM deploys 40.3% of Rev ($19M) (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($54M) (0 disclosures) for IRWD.
IRWD screens cheaper on headline valuation multiples. BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin), whereas IRWD trades at 12.3x Forward P/E, 5.2x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (51.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGM (-7.4% ROE) versus IRWD (-574.7% ROE) capital efficiency.
In options market volatility and institutional positioning, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk). By comparison, IRWD carries 90.5% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.23β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.